Vaxart, Inc. · OTC:VXRT
Vaxart — Raymond James Virtual Human Health Innovation Conference 2020
15 slides from Vaxart's conference presentation, Jun 18, 2020
Slide 1: The Pill Against Pandemics: A Disruptive Oral Vaccine Platform
ep VAXART The Pill Against Pandemics A Disruptive Oral Vaccine Platform Raymond James Virtual Human Health Innovation Conference June 18, 2020
Slide 2: Forward-Looking Statement
Forward-Looking Statement This presentation contains forwardlooking statements that involve substanbal risks and uncertaines. All statements, other than statements of historical facts, included inthis presentation regarding Vaxart’s stategy, prospects, plans and objectives, results from precinical a
Slide 3: Disruptive Oral Vaccine Platform
Disruptive Oral Vaccine Platform Vaccine as a pill VAXART Convenient mode of administration No needles, self administration (no appointments, no lines, social distancing) Potential best-in-class efficacy against COVID-19 and other airborne viruses Activates mucosal immunity, first line of defense, p
Slide 4: Environmentally friendly vaccination campaigns
Environmentally friendly vaccination campaigns Even in large scale » ACOVID-19 vaccination campaign would include ... = 200+ million in the US = 2-3+ billion globally X 3 Billion
Slide 5: Protection by harnessing the multifunctionality of the mucosal immune system
Protection by harnessing the multifunctionality of the mucosal immune system Respiratory Viruses : The Vaxart platform gets the right molecule to the right place Respiratory Viruses Evidence suggesting a Mucosal Correlate or Surrogate of Protection Respiratory act + Influenza (IgA, «487 IgA ASC*) +
Slide 6: Proven Efficacy: Protection against a pandemic respiratory pathogen (2009 H1N1 influenza) after oral tablet delivery
Proven Efficacy: Protection against a pandemic respiratory pathogen (2009 H1N1 influenza) after oral tablet delivery HIN1 Pandemic vaccine made rapidly, tested in animals in a matter of weeks Phase II human challenge study comparing Vaxart's oral tablet vaccine and Sanofi's Fluzone injectable flu va
Slide 7: Safe, with Tolerability Comparable to Placebo
Safe, with Tolerability Comparable to Placebo BARDA-funded flu study Subjects with Solicited Pain at injection site ‘Tendernessat injection site ‘Symptom TEAES: Placebo 42% 12.8% 2.8% n=36 VXAALA 29% 29% 43% n=70 Fluzone 36% 72 460 patients in safety database, dosed across 3 viruses ~ Flu: 245 - Inf
Slide 8: Oral COVID-19 Vaccine Development
Oral COVID-19 Vaccine Development Vaxart Program is Advancing Expeditiously + Final vaccine candidate selected with the potential to generate broad responses + COVID-19 is a respiratory tract infection and this vaccine will promote mucosal and ‘systemic immune responses IgG antibody titers to Covid
Slide 9: Advantages of our COVID-19 vs others
Advantages of our COVID-19 vs others Vector-based Janssen 1Ad26 injected fF ART
Slide 10: Oral COVID-19 Vaccine - Phase Ready
Oral COVID-19 Vaccine - Phase 1 Ready CEES CDMO Partners emergent i. KindredBio * Tech Transfers Complete * GMP Bulk Vaccine in Progress * Clinical/Regulatory Activities + IND submission in June + Clinical Study FP! Summer 2020 + Phase 1 open label, dose ranging > VAKART 10
Slide 11: Prophylactic & Therapeutic Oral Vaccine Candidates
Prophylactic & Therapeutic Oral Vaccine Candidates PROPHYLACTIC VACCINES Novos? Baent EEE Monovalent _—_——————— Seasonal ners? vet Influenza UniversaP = yanssen | AE con09 == sv — THERAPEUTIC VACCINES cos a 2) len Phase 1 drone gh ASC response ref 5059 fr Siar 78-86% fer GLa. 2} Menorlet ava complet
Slide 12: Norovirus Vaccine $3B+ U.S. Market
Norovirus Vaccine $3B+ U.S. Market Government Policy will Drive Demand Age “Population US. Price Target $60! Prospect of ACIP recommendation Low High Percent vaccinated? 4% ost Market potential S058 S16B+ Development / Competitive Status + Vaxert vaccine Phase 1 complete ~ + Phase 2Ready + Challenge
Slide 13: Management Team with Deep Experience in Vaccines
Management Team with Deep Experience in Vaccines € ANDRE! FLOROIU, MBA sratgy, porate Finance, Gun Estes ous, Biopharma Inesing, Vaccines od B) SEAN TUCKER, PHD ‘Mucosal immunology @ Founder and Ciel Scenic Ofcer Gene Deliery @ENTERIC systemic SHAILY JAINI GARG bal Cincal Development, Q Serimen SVP.
Slide 14: Highlights
Highlights + Disruptive Oral vaccine platform * Validated approach: BARDA-funded flu challenge study = Could emerge as the ideal solution for COVID-19 © Potentially best in class efficacy: mucosal & systemic immunity © Appeal of oral administration, low cost across supply chain, environmentally frie
Slide 15: VAXART: The Pill Against Pandemics
ep VAXART The Pill Against Pandemics A Disruptive Oral Vaccine Platform Raymond James Virtual Human Health Innovation Conference June 18, 2020
Vaxart — Raymond James Virtual Human Health Innovation Conference 2020 on 6ix